search
Back to results

Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

Primary Purpose

Seasonal Allergic Rhinitis

Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
UR-63325
Fluticasone propionate nasal spray
Placebo
Sponsored by
Palau Pharma S.L.U.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Seasonal Allergic Rhinitis

Eligibility Criteria

18 Years - 55 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Provision of written informed consent to participate (prior to any study-related procedures being performed) as shown by a signature on the volunteer consent form and to be able to adhere to the study restrictions and examination schedule
  • Subjects with confirmed history of seasonal allergic rhinitis to grass pollen (by direct questioning of presence of positive skin prick test to pollen and History of Symptoms of allergic rhinitis) within the previous two years
  • Positive skin prick test to timothy grass pollen (wheal difference with negative control ≥ 3 mm) at screening
  • Subjects with positive response to screening nasal challenge with increasing doses of timothy grass pollen (Symptoms worsening with respect to the response to the diluent challenge of ≥4 points in the total nasal symptom score [TNSS]) within one hour after last nasal allergen challenge
  • Screening and baseline FEV1 >80% predicted and FEV1/FVC > 70% predicted

Exclusion Criteria:

  • Symptoms of allergic rhinitis within 2 weeks prior to screening
  • Upper respiratory infection or sinusitis within 14 days of screening and also within 14 days of study start in each of the two periods
  • Structural nasal abnormalities or nasal polyps on examination, a history of nose bleeding or recent nasal surgery
  • History of asthma or asthmatic symptoms or other respiratory disease other than rhinitis within the last 2 years or FEV1<80% of predicted at screening or baseline

Sites / Locations

  • Parexel International GmbH

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

UR-63325

Fluticasone propionate nasal spray

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Nasal and ocular symptoms scores after nasal allergen challenge

Secondary Outcome Measures

Inflammatory parameters measured from nasal exudate

Full Information

First Posted
December 13, 2010
Last Updated
April 14, 2011
Sponsor
Palau Pharma S.L.U.
search

1. Study Identification

Unique Protocol Identification Number
NCT01260753
Brief Title
Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge
Official Title
Double Blind Randomised Placebo and Active Controlled, Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge to Allergic Patients Otherwise Healthy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Palau Pharma S.L.U.

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to explore the activity of UR-63325 in a model of allergic rhinitis induced by nasal allergen challenge to known allergic rhinitis patients otherwise healthy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Seasonal Allergic Rhinitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
UR-63325
Arm Type
Experimental
Arm Title
Fluticasone propionate nasal spray
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
UR-63325
Intervention Description
UR-63325
Intervention Type
Drug
Intervention Name(s)
Fluticasone propionate nasal spray
Intervention Description
Fluticasone propionate nasal spray
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo to UR 63325 and fluticasone propionate nasal spray
Primary Outcome Measure Information:
Title
Nasal and ocular symptoms scores after nasal allergen challenge
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Inflammatory parameters measured from nasal exudate
Time Frame
24 hours

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Provision of written informed consent to participate (prior to any study-related procedures being performed) as shown by a signature on the volunteer consent form and to be able to adhere to the study restrictions and examination schedule Subjects with confirmed history of seasonal allergic rhinitis to grass pollen (by direct questioning of presence of positive skin prick test to pollen and History of Symptoms of allergic rhinitis) within the previous two years Positive skin prick test to timothy grass pollen (wheal difference with negative control ≥ 3 mm) at screening Subjects with positive response to screening nasal challenge with increasing doses of timothy grass pollen (Symptoms worsening with respect to the response to the diluent challenge of ≥4 points in the total nasal symptom score [TNSS]) within one hour after last nasal allergen challenge Screening and baseline FEV1 >80% predicted and FEV1/FVC > 70% predicted Exclusion Criteria: Symptoms of allergic rhinitis within 2 weeks prior to screening Upper respiratory infection or sinusitis within 14 days of screening and also within 14 days of study start in each of the two periods Structural nasal abnormalities or nasal polyps on examination, a history of nose bleeding or recent nasal surgery History of asthma or asthmatic symptoms or other respiratory disease other than rhinitis within the last 2 years or FEV1<80% of predicted at screening or baseline
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rainard Fuhr, MD
Organizational Affiliation
Parexel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Parexel International GmbH
City
Berlin
ZIP/Postal Code
14050
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

We'll reach out to this number within 24 hrs